Clinical Guides
Alcohol-Associated Liver Disease
An evidence-led guide to the full spectrum of alcohol-associated liver disease, integrating withdrawal safety, nutrition, prognostic assessment, addiction care and transplant referral in India.
MedNext Academy | 15 min read
Alcohol-Associated Liver Disease
An evidence-led guide to the full spectrum of alcohol-associated liver disease, integrating withdrawal safety, nutrition, prognostic assessment, addiction care and transplant referral in India.
Summary
Alcohol-associated liver disease (ALD) is liver injury caused or accelerated by alcohol exposure, spanning steatosis, steatohepatitis, fibrosis, cirrhosis, hepatocellular carcinoma and the distinct acute presentation of alcohol-associated hepatitis (AH). The requested legacy slug uses ‘alcoholic’, but person-first terms are preferred because a diagnosis should not become a label. ALD and alcohol use disorder (AUD) overlap often but not invariably: liver vulnerability differs between people, and a person with severe AUD may have little recognized liver disease while another develops advanced injury at a lower reported exposure.
Assessment has two simultaneous tracks. The liver track determines inflammation, fibrosis, portal hypertension, decompensation, infection, renal injury and short-term mortality. The alcohol track establishes current use, dependence, prior withdrawal, treatment goals, mental health and social safety. A patient who is dependent must not simply be told to stop abruptly without withdrawal risk assessment. Conversely, detoxification alone is not durable ALD treatment. Sustained alcohol abstinence offers the greatest long-term benefit, and outcomes improve when hepatology and addiction teams provide integrated, non-punitive care.
Early ALD can be silent; normal aminotransferases do not exclude fibrosis. Advanced disease may present with ascites, encephalopathy, gastrointestinal bleeding, jaundice or infection. Probable AH is a syndrome of recent jaundice after sustained heavy exposure, supported by a characteristic biochemical pattern after competing causes are excluded. Severe AH generally requires hospital care, nutritional support, infection assessment and prognostic scoring; selected eligible patients may receive corticosteroid-based treatment with early response review. Decompensated cirrhosis and non-responsive severe AH warrant timely transplant consideration. No arbitrary abstinence duration should replace individualized medical and psychosocial selection.
How Common Is It?
Alcohol causes a large but unevenly distributed burden. WHO’s 2024 global report estimates that alcohol consumption contributed to 2.6 million deaths in 2019 and documents a major treatment gap for alcohol and drug use disorders. Those figures describe all alcohol-attributable harm, not ALD prevalence, and should not be converted into a liver-specific numerator. The burden reflects beverage strength, patterns of heavy episodic and sustained use, sex, nutrition, metabolic disease, viral hepatitis, access to treatment and broader social determinants. Recorded sales also miss unrecorded or illicit alcohol.
ALD is underdetected because steatosis and compensated fibrosis may cause no symptoms, because routine liver tests lack sensitivity for fibrosis, and because shame discourages disclosure. Hospital statistics overrepresent severe AH and decompensated cirrhosis while missing earlier disease in primary care. A falling aminotransferase level in advanced failure can falsely reassure, and a high level does not measure fibrosis. Population comparisons must specify whether they report harmful exposure, AUD, steatosis, cirrhosis, AH admissions, transplant listing or mortality.
India has substantial regional, sex and socioeconomic variation in alcohol availability, beverage type, abstention and treatment access. National survey estimates of use are not interchangeable with clinically confirmed ALD, and local hospital series cannot establish national prevalence. Unrecorded spirits may carry additional poisoning risk, but methanol toxicity is not ALD. Women can develop injury at lower cumulative exposure and may face greater barriers to care; this is a biological and service equity observation, not a moral judgement. The actionable response is case-finding in people with harmful use, AUD or liver-risk comorbidity using history, liver tests and validated non-invasive fibrosis assessment, followed by linkage to treatment rather than population labels.
Risk Factors
Cumulative alcohol dose and pattern are major determinants, but there is no threshold that guarantees safety for an individual liver. Clarify beverage, volume, strength, frequency, heavy episodes, duration, recent change and periods of abstinence; translate local measures into approximate grams of ethanol without implying false precision. Home-poured spirits, country liquor and shared bottles make standard-drink counts unreliable. Ask neutrally and revisit the history after rapport develops. Biomarkers can support a formulation but do not replace consent, context or conversation.
Susceptibility increases with female sex, obesity, diabetes and other metabolic risk, tobacco use, chronic hepatitis B or C, and genetic factors. Alcohol can accelerate another liver disease, so finding viral hepatitis, metabolic dysfunction, autoimmune disease or a hepatotoxic medicine does not make exposure irrelevant. Malnutrition and sarcopenia worsen resilience, while obesity and undernutrition may coexist. Family history can suggest shared genes and environments but must not be used deterministically. Socioeconomic adversity, trauma, mental illness, pain, hazardous work and limited treatment access influence both exposure and recovery.
Progression risk is higher with established fibrosis, continued drinking after diagnosis and repeated AH or decompensation. A prior withdrawal seizure or delirium predicts dangerous future withdrawal but not necessarily liver severity. Infection, gastrointestinal bleeding, nephrotoxins, dehydration and sedatives can precipitate acute decompensation. Stigma is itself a clinical risk: pejorative documentation, coercive confrontation or transplant moralising can drive avoidance and concealment. Use ‘person with AUD’ and ‘alcohol-associated’ disease, ask permission to discuss alcohol, and separate accountability for a treatment plan from blame. Evidence about exact individual risk at low exposure remains uncertain; population dose-response associations cannot predict a single patient’s course.
Diagnosis
History
Establish jaundice, dark urine, abdominal distension, oedema, haematemesis, melaena, confusion, fever, weight and muscle loss, pruritus and reduced intake. Obtain an empathetic alcohol timeline, last drink, morning use, loss of control, prior treatment, withdrawal tremor, hallucinations, seizures or delirium. Ask about viral risks, obesity, diabetes, medicines, herbal products, family history, depression, suicide risk and social support. Collateral history may help with consent. Do not delay emergency care while trying to prove an exact lifetime dose.
Examination
Record mental state, vital signs, hydration, nutrition and signs of withdrawal. Look for jaundice, hepatomegaly, splenomegaly, ascites, oedema, muscle wasting, bruising and cutaneous markers of chronic liver disease. Asterixis suggests encephalopathy but is not specific. Fever, hypotension, abdominal tenderness, hypoxia or reduced urine output raise infection and organ-failure concern. Assess capacity, safeguarding and Wernicke features. Rectal examination or nasogastric procedures are indication-led and require consent and competence.
Investigations
Obtain full blood count, electrolytes, urea, creatinine, glucose, liver panel, albumin, INR and tests for competing causes. AST often exceeds ALT in AH, but neither ratio nor gamma-GT proves causation. Ultrasound assesses morphology, steatosis, biliary obstruction, ascites, spleen and portal flow; non-invasive blood scores and elastography estimate fibrosis, interpreted cautiously during active inflammation and recent drinking. Ascites of new onset or hospital decompensation usually needs diagnostic paracentesis. Evaluate infection actively in suspected AH. Probable AH uses recent onset or worsening jaundice, relevant exposure and a compatible pattern after exclusion of alternatives. Biopsy is reserved for diagnostic uncertainty when the result changes treatment. Calculate MELD for severity; use Maddrey discriminant function only with correctly matched laboratory units and control prothrombin time.
Differential Diagnosis
Metabolic dysfunction-associated steatotic liver disease commonly coexists with alcohol exposure. The task is not to award one exclusive label but to identify each modifiable driver and the dominant clinical syndrome. Acute viral hepatitis, chronic hepatitis B or C, autoimmune hepatitis, drug- or supplement-induced injury, ischaemic hepatitis, biliary obstruction and sepsis-related cholestasis can resemble AH. Very high aminotransferases, an atypical timeline or absent jaundice should prompt reconsideration. Wilson disease is important in younger patients; haemochromatosis, alpha-1 antitrypsin deficiency and vascular liver disease are tested selectively.
Jaundice with abdominal pain may arise from choledocholithiasis, cholangitis or pancreatitis. Fever and leukocytosis can occur in AH but must not be assumed sterile: spontaneous bacterial peritonitis, pneumonia, urinary infection, skin infection and sepsis are common and alter steroid safety. Ascites and oedema also occur with heart failure, nephrotic syndrome, malignancy and tuberculosis. Confusion may reflect hypoglycaemia, intoxication, withdrawal, Wernicke encephalopathy, head injury, meningitis, uraemia, medication or hepatic encephalopathy; several can coexist.
In established cirrhosis, acute deterioration may represent gastrointestinal bleeding, infection, portal-vein thrombosis, drug injury, dehydration, acute kidney injury or hepatocellular carcinoma rather than ‘more drinking’ alone. Methanol or other toxic-alcohol exposure causes metabolic and neurological toxicity and needs a poison pathway, not an ALD pathway. Gilbert syndrome does not explain synthetic dysfunction or ascites. When exposure history is uncertain, maintain respectful diagnostic uncertainty and investigate alternatives rather than using a stigmatizing shortcut. Histology can distinguish patterns in selected ambiguous severe presentations but is invasive, is not required for a typical probable AH syndrome, and cannot determine a person’s motivation or future behaviour.
Management
Stabilize emergencies first: resuscitate bleeding or shock, treat sepsis, correct hypoglycaemia, assess airway and encephalopathy, and involve senior liver care. Determine whether the last drink and dependence create imminent withdrawal risk. Monitored withdrawal treatment is separate from long-term relapse prevention and must account for cirrhosis, cognition, falls and respiratory risk. Give parenteral thiamine promptly when Wernicke encephalopathy is suspected or risk is high; do not wait for imaging. Never advise an at-risk dependent patient to undertake abrupt, unobserved withdrawal at home.
For all ALD stages, offer alcohol treatment without confrontation. Use motivational interviewing, evidence-based psychosocial intervention and, where appropriate, AUD medication selected with addiction and liver expertise. Integrate hepatology, psychiatry or addiction medicine, nursing, nutrition and social work. Agree a relapse plan that invites rapid return rather than discharge for recurrence. Treat tobacco use, metabolic risk, viral hepatitis and vaccination needs. Compensated cirrhosis requires portal-hypertension assessment, hepatocellular-carcinoma surveillance and prevention of decompensation according to cirrhosis guidance. Ascites, variceal bleeding, encephalopathy and infection need their own protocols.
Hospitalize severe AH, commonly defined by MELD above 20, and address infection, renal function and nutrition. In an eligible patient, corticosteroids may improve short-term survival; screen contraindications and reassess response using the Lille score at day four or seven, stopping treatment in non-response. Intravenous N-acetylcysteine can be used as an adjunct under the recommended regimen. Do not use pentoxifylline routinely. Prognostic scores support, but do not replace, clinical judgement. Discuss transplant early for decompensated disease or medically unresponsive severe AH, and palliative care when transplant and recovery are not achievable. Sustained abstinence remains the strongest long-term intervention, but compassionate care continues after recurrence.
Prescribing Information
Alcohol withdrawal prescribing requires a monitored protocol. Benzodiazepines are first-line for clinically significant withdrawal, but agent, dose and setting depend on severity, previous seizures or delirium, age, respiratory status and liver function. In advanced liver disease, shorter-acting agents with less dependence on hepatic oxidative metabolism, such as lorazepam or oxazepam, are often preferred; oversedation can mimic or worsen encephalopathy. Symptom-triggered regimens require trained observation and are unsafe where scoring is unreliable. Severe withdrawal, seizures, delirium, pregnancy, major comorbidity or poor home support generally needs inpatient care. Thiamine replacement should accompany treatment, with urgent parenteral therapy for suspected Wernicke encephalopathy.
AUD relapse-prevention medication must be individualized. The ACG guideline supports baclofen in compensated ALD and conditionally suggests acamprosate or naltrexone in compensated disease, as well as gabapentin or topiramate in selected patients; evidence is limited and renal, hepatic, neurological and adherence factors matter. Avoid disulfiram across the ALD spectrum because of hepatotoxicity. Naltrexone is not appropriate with current opioid use and needs liver-stage assessment. These medicines should reinforce, not replace, psychosocial treatment, and local Indian availability and licensing must be checked.
For severe AH, specialist prednisolone treatment is considered after infection, gastrointestinal bleeding, renal failure and other contraindications are assessed. ACG recommends corticosteroid therapy for severe disease and intravenous N-acetylcysteine as an adjunct, then Lille response assessment at day four or seven; discontinue steroid in non-response. Do not continue because bilirubin ‘looks a little better’ without structured review. Avoid routine prophylactic antibiotics, pentoxifylline, unproven microbiome products or granulocyte colony-stimulating factor outside appropriate protocols or research. Dose all medicines for hepatic and renal function, avoid unnecessary sedatives and NSAIDs in decompensated cirrhosis, and reconcile herbal products explicitly.
When to Refer
Send immediately to emergency care for haematemesis or melaena, shock, severe confusion, seizure, delirium, suspected Wernicke encephalopathy, sepsis, hypoglycaemia, rapidly worsening jaundice, respiratory compromise, severe abdominal pain or inability to maintain intake. Suspected severe withdrawal should not wait in an unmonitored outpatient area. New ascites, encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, acute kidney injury or marked coagulopathy indicates decompensation and specialist or hospital management. A patient with probable AH and MELD above 20 should preferably be hospitalized.
Refer to gastroenterology or hepatology for suspected advanced fibrosis, portal hypertension, persistent synthetic dysfunction, uncertain diagnosis, focal liver lesion, recurrent decompensation or consideration of disease-specific treatment. Non-invasive fibrosis tests can triage, but active inflammation and alcohol-related thrombocytopenia can distort estimates. Referral information should include alcohol timeline and last drink, withdrawal history, mental-health risk, examination, serial bilirubin and creatinine, INR, sodium, platelets, infection evaluation, ultrasound and current medicines. Use nonjudgmental wording and do not make specialist access conditional on perfect abstinence.
Transplant referral should occur with decompensated cirrhosis, hepatocellular carcinoma within a transplant pathway, or selected severe AH unresponsive to medical therapy and at high risk of death. Selection is multidisciplinary and examines medical benefit, relapse risk, engagement, social stability and capacity for follow-up; a fixed six-month abstinence rule is not a substitute for assessment. Refer simultaneously for addiction care, nutrition and psychosocial support. In India, route through a centre with hepatology, critical care, transplant surgery and addiction capacity when feasible. Financial counselling and state or institutional assistance may be needed, but lack of funds must not prevent honest prognosis, symptom care or referral discussion.
Red Flags
Upper gastrointestinal bleeding is a medical emergency: haematemesis, coffee-ground vomit, melaena, syncope or shock in possible cirrhosis requires resuscitation and a variceal-bleeding pathway. New confusion, drowsiness, asterixis or personality change may be hepatic encephalopathy, but check glucose, oxygenation, infection, head injury, intoxication, withdrawal and sedative exposure. Fever, hypotension, increasing ascites, abdominal tenderness, hypoxia, oliguria or rising creatinine may signal spontaneous bacterial peritonitis, other sepsis or acute-on-chronic liver failure. Diagnostic and treatment delays can be fatal.
Withdrawal red flags include prior delirium tremens or withdrawal seizure, severe tremor, agitation, hallucinations, disorientation, autonomic instability, repeated vomiting and seizures. Symptoms can evolve after presentation and can coexist with hepatic encephalopathy; a single alcohol level or calm examination does not establish safety. Ataxia, eye-movement abnormality, confusion, hypothermia or hypotension raises Wernicke encephalopathy and warrants immediate parenteral thiamine. Suicidal intent, violence risk, abuse, inability to care for dependants or unsafe housing requires parallel crisis and safeguarding action.
Rapidly increasing jaundice, INR or creatinine, severe hyponatraemia, hypoglycaemia, tense ascites, refractory symptoms and multi-organ failure indicate high short-term risk. Unintentional weight loss, progressive focal pain, a liver mass or deterioration despite abstinence requires assessment for hepatocellular carcinoma or another diagnosis. Never reassure from a falling AST or ALT when synthetic function worsens. After discharge, safety-net fever, bleeding, confusion, reduced urine, abdominal enlargement, persistent vomiting, recurrent drinking with withdrawal risk and inability to obtain food or medicines. Make emergency contact instructions specific and understandable to the patient and chosen family member.
Indian Clinical Context
Indian care must connect liver and addiction services that often operate separately. A district hospital may manage withdrawal or decompensation, a psychiatry or drug-dependence service may treat AUD, and a medical-college hepatology unit may stage fibrosis or evaluate transplant. The MoHFW Standard Treatment Guideline for alcohol dependence provides a national reference for assessment, detoxification and longer-term treatment, but its 2016 fixed-dose examples are dated and must not override current hospital protocols, individual liver impairment or monitored symptom assessment. Referral should pass information in both directions so that discharge from one service does not end the other treatment track.
Ask about locally used spirits, home pours and unrecorded beverages without stereotyping region, caste, occupation or income. Methanol outbreaks need toxicology action and should not be misclassified as chronic liver injury. Discuss alcohol privately before inviting family participation; family support can help, but consent, domestic safety and confidentiality matter. Women and marginalized patients may experience disproportionate shame or barriers. Use person-first language in notes, avoid ‘alcoholic’ as a noun, and never withhold analgesia, infection treatment or referral as punishment for relapse. Recurrence is a signal to intensify care, not evidence that care is futile.
Nutrition advice should use affordable foods and the patient’s preferences: frequent meals, a late snack, adequate pulse, dairy, egg, fish, meat or other acceptable protein, and oral supplements when ordinary intake is insufficient. Do not prescribe protein restriction for routine encephalopathy; assess sarcopenia and micronutrient risk. Severe malnutrition or prolonged poor intake requires refeeding-risk planning. Transplant access is concentrated and costly, so referral must begin early, with transparent discussion of centre criteria and financial support. International ACG targets and transplant recommendations are evidence comparators, not Indian entitlement rules. Local formulary, organ-allocation law, state pathways and centre protocols govern actual care.
NMC Competency Mapping
The NMC CBME Curriculum 2024 maps the disease directly. PA24.4 requires description of the pathophysiology, pathology and progression of alcoholic liver disease including cirrhosis. PA24.5 covers the aetiology, pathogenesis and complications of portal hypertension, and PA24.6 requires performance-level interpretation of liver-function and viral-hepatitis panels to distinguish obstructive from non-obstructive jaundice. In General Medicine, GM5.4 addresses pathophysiology and clinical evolution of ALD, while GM5.5 covers cirrhosis and portal-hypertension complications including ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, encephalopathy, acute gastrointestinal bleeding and hepatocellular carcinoma.
Clinical integration continues through GM5.6 on causes and evaluation of jaundice, GM5.14 on assisting with and interpreting ascitic-fluid analysis, and GM5.15 on management of hepatitis, cirrhosis, portal hypertension and major complications. Learners should connect pathology to decisions: recognize probable AH, assess severity, search for infection, interpret synthetic function, identify decompensation, calculate a prognostic score from supplied data and explain why AUD treatment changes survival. Communication assessment should reward non-stigmatizing alcohol history, capacity assessment and withdrawal safety.
A useful OSCE contrasts an asymptomatic person with harmful use and fibrosis risk, a jaundiced patient with probable severe AH, and a person with cirrhosis plus confusion or bleeding. Students must prioritize resuscitation, glucose, sepsis and withdrawal risk rather than recite liver enzymes. They can counsel and participate in supervised care, but independent detoxification prescribing, paracentesis, steroid eligibility decisions and transplant selection exceed undergraduate authority. Curriculum wording retains the older ‘alcoholic’ label; teaching should explain the modern person-first terminology without altering the quoted competency. This draft remains an educational review candidate, not a completed clinical endorsement.
Key Exam Pearls for NEET PG
ALD progresses through steatosis, steatohepatitis, fibrosis and cirrhosis, with AH as a clinical syndrome of recent jaundice on a background of sustained heavy exposure. AST is often greater than ALT and values are commonly modest in AH; extreme aminotransferase elevation suggests alternatives such as ischaemia, toxin or acute viral hepatitis. Gamma-GT supports exposure context but is neither sensitive nor specific enough to diagnose ALD. INR, bilirubin, creatinine, sodium, encephalopathy and complications reflect severity more meaningfully than enzyme height. Fibrosis assessment uses validated non-invasive tests, with caution during active inflammation.
MELD above 20 identifies severe AH in the ACG framework and supports hospitalization and treatment assessment. Maddrey discriminant function is an older severity tool and requires the laboratory control prothrombin time. The Lille score evaluates response after four or seven days of corticosteroid therapy; a value above 0.45 indicates non-response and steroids should be stopped. Pentoxifylline is not recommended. Nutrition is treatment: aim around 35 kcal/kg/day and 1.2-1.5 g/kg/day protein in AH, adding oral then enteral support when intake is insufficient, while managing refeeding risk individually.
Do not confuse alcohol withdrawal with hepatic encephalopathy: both may coexist, and benzodiazepine oversedation is hazardous in liver failure. Thiamine is urgent when Wernicke encephalopathy is suspected. Sustained abstinence is the major long-term prognostic intervention, best achieved through integrated AUD care. Decompensated cirrhosis is managed by standard complication pathways and triggers transplant referral. Carefully selected severe AH nonresponders may receive early transplant consideration; an automatic six-month rule is not evidence-based selection. PA24.4 and GM5.4 are the direct ALD competencies, while GM5.5 and GM5.15 connect cirrhosis complications to management.
Frequently Asked Questions
Can someone with alcohol-associated liver disease stop drinking immediately at home?
Abstinence is the long-term goal, but abrupt unmonitored cessation can be dangerous when dependence is present. Previous withdrawal seizure or delirium, severe tremor, hallucinations, major medical illness, pregnancy or poor support usually requires supervised care. A clinician should assess the last drink, prior withdrawal and current liver status, arrange thiamine and monitored treatment when indicated, and link detoxification to ongoing AUD care.
Do normal liver enzymes rule out alcohol-associated fibrosis or cirrhosis?
No. Aminotransferases may be normal or only mildly abnormal despite substantial fibrosis, and they can fall as advanced liver failure reduces viable hepatocyte mass. Assessment uses history, platelet count, synthetic function, validated non-invasive fibrosis scores, imaging and elastography where appropriate. Active drinking and inflammation can distort some measures, so results require clinical interpretation rather than a single-test reassurance.
Should protein be restricted when cirrhosis causes hepatic encephalopathy?
Routine protein restriction is not recommended because it worsens sarcopenia and malnutrition. Patients with AH commonly need roughly 1.2-1.5 g/kg/day of protein and adequate energy, individualized by the treating dietitian and liver team. Use frequent meals and a late snack, correct micronutrient deficiencies, and add oral or enteral support if intake is inadequate while monitoring refeeding risk.
Is six months of abstinence always required before liver transplant referral?
No fixed duration should delay referral for a person with decompensated cirrhosis or severe AH at high risk of death. Transplant centres use multidisciplinary medical and psychosocial assessment, local allocation rules, expected benefit, engagement and relapse-risk formulation. Sustained abstinence remains important, but carefully selected nonresponders with severe AH may be considered for early transplantation under centre protocols.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic